External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease

British Journal of Cancer

Volumn 100, Issue 6, 2009, Pages 979-984

  Kerkmeijer, L G ^a   Thomas, C M ^a   Harvey, R ^b   Sweep, F C ^a   Mitchell, H ^b   Massuger, L F ^a   Seckl, M J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Combination chemotherapy; Drug resistance; Methotrexate; Persistent trophoblastic disease; Single agent chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COMBINATION CHEMOTHERAPY; CONTROL GROUP; CONTROLLED STUDY; GONADOTROPIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPEATED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TREATMENT DURATION; TROPHOBLASTIC DISEASE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORIONIC GONADOTROPIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; TROPHOBLASTIC NEOPLASMS;

EID: 62549127788     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604849     Document Type: Article

References (16)

1. Bagshawe KD, Dent J, Newlands ES, Begent RH, Rustin GJ (1989) The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 96: 795-802
2. Bower M, Rustin GJ, Newlands ES, Holden L, Short D, Foskett M, Bagshawe KD (1998) Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur J Cancer 34: 1204-1207, doi:10.1016/S0959-8049(98) 00059-8
3. Cole LA, Sutton JM (2004) Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. J Reprod Med 49: 545-553
4. Delfs E (1957) Quantitative chorionic gonadotropin: prognostic value in hydatidiform mole and chorionepithelioma. Obstet Gynecol 9: 1-23
5. Dobson LS, Lorigan PC, Coleman RE, Hancock BW (2000) Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high-risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer 82: 1547-1552, doi:10.1054/bjoc.2000.1176
6. FIGO Oncology Committee (2002) FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 77: 285-287, doi:10.1016/S0020-7292(02)00063-2
7. Garrett AP, Garner EO, Goldstein DP, Berkowitz RS (2002) Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 47: 355-362
8. Hayes DF, Bast RC, Desch CE, Fritsche Jr H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Nat Cancer Inst 88: 1456-1466
9. Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K, Sekiya S (2005) Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol 96: 616-620, doi:10.1016/j.ygyno.2004.11.011
10. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES (2002) Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20: 1838-1844, doi:10.1200/JCO.2002. 07.166
11. Rotmensch J, Rosenhein NB, Block BS (1988) Comparison of human chorionic gonadotropin regression in molar pregnancies and post-molar nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 29: 82-86
12. Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D (1996) Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 14: 2769-2773
13. Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands ES (2000) Choriocarcinoma and partial hydatidiform moles. Lancet 356: 36-39, doi:10.1016/S0140-6736(00)02432-6
14. Shigematsu T, Hirakawa T, Yahata H, Sonoda T, Kinukawa N, Nakano H (2003) Identification of chemotherapeutic refractory cases based on human chorionic gonadotropin values among patients with low-risk persistent trophoblastic disease treated with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 24: 113-116
15. Van Trommel NE, Massuger LF, Schijf CP, ten Kate-Booij MJ, Sweep FC, Thomas CM (2006) Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 24: 52-58, doi:10.1200/JCO.2005.03.3043
16. Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E (2004) Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy. Obstet Gynecol 104: 551-554, doi:10.1097/01.AOG.0000136099.21216.45